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Summary
Background Lassa fever is a viral haemorrhagic fever endemic in parts of west Africa. New treatments are needed to 
decrease mortality, but pretrial reference data on the disease characteristics are scarce. We aimed to document 
baseline characteristics and outcomes for patients hospitalised with Lassa fever in Nigeria.
Methods We did a prospective cohort study (LASCOPE) at the Federal Medical Centre in Owo, Nigeria. All patients 
admitted with confirmed Lassa fever were invited to participate and asked to give informed consent. Patients of all 
ages, including newborn infants, were eligible for inclusion, as were pregnant women. All participants received 
standard supportive care and intravenous ribavirin according to Nigeria Centre for Disease Control guidelines and 
underwent systematic biological monitoring for 30 days. Patients’ characteristics, care received, mortality, and 
associated factors were recorded using standard WHO forms. We used univariable and multivariable logistic 
regression models to investigate an association between baseline characteristics and mortality at day 30.
Findings Between April 5, 2018, and March 15, 2020, 534 patients with confirmed Lassa fever were admitted to 
hospital, of whom 510 (96%) gave consent and were included in the analysis. The cohort included 258 (51%) male 
patients, 252 (49%) female patients, 426 (84%) adults, and 84 (16%) children (younger than 18 years). The median 
time between first symptoms and hospital admission was 8 days (IQR 7–13). At baseline, 176 (38%) of 466 patients 
had a Lassa fever RT-PCR cycle threshold (Ct) lower than 30. From admission to end of follow-up, 120 (25%) of 484 
reached a National Early Warning Score (second version; NEWS2) of 7 or higher, 67 (14%) of 495 reached a Kidney 
Disease–Improving Global Outcome (KDIGO) stage of 2 or higher, and 41 (8%) of 510 underwent dialysis. All patients 
received ribavirin for a median of 10 days (IQR 9–13). 62 (12%) patients died (57 [13%] adults and five [6%] children). 
The median time to death was 3 days (1–6). The baseline factors independently associated with mortality were 
the following: age 45 years or older (adjusted odds ratio 16·30, 95% CI 5·31–50·30), NEWS2 of 7 or higher 
(4·79, 1·75–13·10), KDIGO grade 2 or higher (7·52, 2·66–21·20), plasma alanine aminotransferase 3 or more times 
the upper limit of normal (4·96, 1·69–14·60), and Lassa fever RT-PCR Ct value lower than 30 (4·65, 1·50–14·50).
Interpretation Our findings comprehensively document clinical and biological characteristics of patients with Lassa 
fever and their relationship with mortality, providing prospective estimates that could be useful for designing future 
therapeutic trials. Such trials comparing new Lassa fever treatments to a standard of care should take no more 
than 15% as the reference mortality rate and consider adopting a combination of mortality and need for dialysis as the 
primary endpoint.
Funding Institut National de la Santé et de la Recherche Médicale, University of Oxford, EU, UK Department for 
International Development, Wellcome Trust, French Ministry of Foreign Affairs, Agence Nationale de Recherches sur 
le SIDA et les hépatites virales, French National Research Institute for Sustainable Development.
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 
license.
Introduction 
Lassa fever is a viral haemorrhagic fever caused by the 
Lassa virus. It is endemic in west Africa, where it has an 
estimated annual burden of 300 000 cases and 
5000–10 000 deaths.1,2 Lassa virus is mainly transmitted 
from a zoonotic reservoir to humans,3 whereas human-
to-human transmission is less frequent and mostly 
nosocomial.4,5 Early symptoms are not very specific, 
often leading health-care workers to suspect another 
diagnosis and causing delays in the appropriate 
management. In severe cases, the course of the disease 
can lead to multiorgan failure and death.3 Most data on 
the natural history of Lassa fever are retrospective or 
from before the development of reliable diagnostic 
tools.6–9 Intravenous ribavirin is the recommended 
specific treatment despite weak evidence of its efficacy6,10 
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and concerns regarding its toxicity.10 No vaccine is 
available yet. For all these reasons, Lassa fever has been 
included in the WHO Research and Development 
Blueprint list of high-priority diseases.
Several antivirals and immunotherapeutics are 
promising candidates for treatment of Lassa fever.11,12 
Before designing drug efficacy trials, it is essential to 
describe the prospective course of Lassa fever and 
estimate the mortality rate and associated factors under 
the best possible standard of care.
In 2018, in the context of an unprecedented seasonal 
recrudescence of Lassa fever,13 we established a Lassa fever 
ward, organised standardised care, and launched a 
prospective cohort of patients with Lassa fever at the 
Federal Medical Centre in Owo (Ondo State, Nigeria).14 In 
this study, we aimed to prospectively study and document 
the characteristics on admission, care received, and 
outcomes of patients registered during the first 24 months 
of this cohort.
Methods 
Patients and setting 
The protocol for the LASCOPE (Lassa fever clinical course 
and prognostic factors in an epidemic context) cohort has 
been published previously.14 Briefly, the Federal Medical 
Centre Owo (FMCO) is a tertiary hospital serving a large, 
semi-urban and rural area in Ondo State, Nigeria. From 
the start of the study period, all patients admitted to the 
emergency room and any other department at the FMCO 
with confirmed Lassa fever were referred to the Lassa 
fever ward and invited to participate in the cohort. Patients 
who signed an informed consent form were included in 
the cohort. Patients of all ages were eligible for inclusion. 
Pregnant women and newborn infants were also eligible 
for inclusion. Lassa fever was confirmed by use of the 
RealStar Lassa Virus RT-PCR kit 2.0 (Altona Diagnostics, 
Hamburg, Germany; details presented in appendix p 4).
Informed consent was sought on admission. For 
underage children (younger than 18 years), the consent 
of at least one parent or guardian was required. The 
assent of the child was also sought for children older 
than 12 years. For adults without the capacity to give 
informed consent, a relative was asked to consent on 
behalf of the patient. When the patient regained the 
capacity to give informed consent, they were asked if they 
agreed to continue to participate. The study was approved 
by the Nigerian National Health Research Ethics 
Committee and the FMCO Research Ethics Committee. 
Confidentiality was guaranteed by deidentification and 
restricted access to study documents and databases.
Follow-up and care of patients 
Following the Nigerian Centre for Disease Control 
guidelines, patients with suspected Lassa fever with a low 
index of suspicion were not started on ribavirin before 
RT-PCR confirmation. Patients with confirmed Lassa 
Research in context
Evidence before this study
Lassa fever is endemic to west Africa, with some reports of 
exported confirmed cases. Lassa fever is responsible for a disease 
burden exceeding that of all other viral haemorrhagic fevers 
except dengue and yellow fever. Prospective cohort evidence is 
needed on mortality and associated factors under the best 
standard of care to inform the design of future therapeutic trials. 
We searched PubMed up to Nov 11, 2020, for publications in 
English using the following search terms: (“Lassa fever” OR 
“Lassa virus”) AND (“retrospective study” OR “prospective study” 
OR “cohort”). Among 19 study reports, only three reported 
mortality and its associated factors among patients with Lassa 
fever confirmed by RT-PCR. All three studies were retrospective, 
and only one study enrolled more than 100 patients.
Added value of this study
We monitored a cohort of 510 participants with RT-PCR-
confirmed Lassa fever admitted over a 24-month period at the 
Federal Medical Centre of Owo, Ondo State, Nigeria. Patients 
received intravenous ribavirin therapy and standardised 
supportive care free of charge, including fluid resuscitation, 
antibiotics, antimalarials, blood transfusions, and renal 
replacement therapy where appropriate. The 30-day mortality 
was 13% for adults and 6% for children. The median time 
between symptom onset and admission to the Lassa fever ward 
was 8 days. 82% of deaths occurred within 7 days of admission. 
The factors associated with mortality were age, the National 
Early Warning Score (second version), baseline Lassa RT-PCR 
cycle threshold value, acute renal failure, and plasma 
aminotransferase level.
Implications of all the available evidence
Lassa fever displays some common characteristics with Ebola 
virus disease and some striking differences, all of which have 
implications for the design of future clinical trials. On one hand, 
as with Ebola, faster diagnosis and management is necessary 
because most patients arrive late and intra-hospital deaths 
occur quickly. Additionally, cycle threshold values for Lassa fever 
RT-PCR appear to be a useful and easy-to-use prognostic tool, 
for both managing clinical cases and stratifying randomisation 
for future trials. Furthermore, acute renal failure is a major 
driver of prognosis and further exploration is needed on 
carefully balancing recourse to fluid resuscitation, vasopressor 
or inotropic drugs, and dialysis in this context. On the other 
hand, mortality from Lassa fever is several times lower than 
that from Ebola. Because a very large number of participants 
would be required for a trial to show the efficacy of new drugs 
in reducing mortality, composite endpoints combining 
mortality with clinically significant parameters should be 
considered for future trials.
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fever and those without confirmation but with a high 
index of suspicion (defined in appendix p 3) were started 
on ribavirin immediately. Different intravenous ribavirin 
regimens were used depending on age, pregnancy status, 
and physician’s preference (appendix p 3).15
Standard supportive care included oral or intravenous 
administration of fluids and analgesics, oxygen according 
to the patient’s clinical status, antimalarials for patients 
with confirmed malaria, antibiotics for patients with 
a suspected bacterial infection, total blood transfusion 
for patients with severe anaemia, and intermittent 
haemodialysis for patients with life-threatening acute 
renal dysfunction. Mechanical ventilation, invasive 
haemodynamic monitoring, vasopressor drugs, and 
inotropic drugs were not available.
Patients underwent systematic biological monitoring, 
including testing for malaria with a rapid diagnostic 
test (SD BIOLINE Malaria Ag P.f, Abbott, Chicago, IL, 
USA) or thick blood smear on hospital admission 
(day 0) and the following tests on day 0, day 5, and 
day 10 of hospital stay: Lassa virus RT-PCR, full blood 
count, albuminaemia, creatininaemia, uraemia, plasma 
electrolytes, aspartate aminotransferase, alanine amino-
transferase, and bilirubin. Women of childbearing age 
underwent a urine pregnancy test at day 0. Additional 
tests were done whenever it was deemed useful.
The criteria for hospital discharge were absence of 
fever or any other substantial symptoms and completion 
of 10 days of ribavirin therapy. Patients meeting the 
criteria for discharge but still having a positive RT-PCR 
test for Lassa virus were discharged with a prescription 
for oral ribavirin for an additional 7 days, as recommended 
in the Nigerian Centre for Disease Control guidelines 
(appendix p 3).15 Patients who were discharged were 
asked to attend an outpatient visit 30 days after admission 
to detect any subacute sequelae requiring specific care.
Data collection and definitions 
We collected demographic characteristics, clinical 
measures and symptoms, the previously mentioned 
biological monitoring, care and treatments received, and 
clinical outcomes. Data were recorded with use of an 
expanded version of the standard WHO Lassa fever case 
report form.14 Clinical severity was scored with the 
National Early Warning Score, version 2 (NEWS2).16 
Acute kidney dysfunction was classified as acute kidney 
injury or acute kidney failure and staged according to 
Kidney Disease–Improving Global Outcome (KDIGO) 
criteria (appendix p 2).17,18 Malaria was defined as 
presentation of signs and symptoms compatible with a 
malaria episode and the presence of asexual forms of 
Plasmodium sp on a thick blood smear or a positive 
malaria rapid diagnostic test.
Pregnancy outcomes were categorised as spontaneous 
miscarriage (spontaneous expulsion of the fetus before 
28 weeks of amenorrhoea), intrauterine death (fetal death 
after 28 weeks of amenorrhoea without fetus expulsion), 
maternofetal demise (concomitant death of the mother 
and the fetus), stillbirth (birth of neonate showing no signs 
of life after 28 weeks of amenorrhoea), and livebirth.19
Statistical analysis 
Hospital admission was defined as day 0. We used the 
Kaplan-Meier method to estimate time to death between 
day 0 and day 30. We used univariable and multivariable 
logistic regression models to investigate an association 
between baseline characteristics and mortality at day 30. 
All cycle threshold (Ct) values used in the analysis were 
Ct values for the GPC gene. Sex was included a priori in 
all multivariable models. Age, Ct value, plasma alanine 
aminotransferase concentration, NEWS2, and KDIGO 
stage were included in all multivariable models provided 
they had p<0∙05 in univariable analysis. All other 
variables with less than 10% of missing values and 
p<0∙05 in univariable analysis were included in the 
initial multivariable model and either kept until the final 
model or excluded before the final model in a stepwise 
descending procedure. We did the main analysis with 
available data. We did a sensitivity analysis including all 
patients with missing data in a specific category for each 
variable to explore whether missing data for key variables 
could influence the final conclusion. Analyses were done 
with use of SAS, version 9.4.
Role of the funding source 
The funders of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. AD, MJ, and DG had access to the 
raw data. The corresponding author had full access to all 
of the data and the final responsibility to submit for 
publication. 
Results 
Between April 5, 2018, and March 15, 2020, 712 patients 
were admitted to the Lassa fever ward with suspected 
Lassa fever, of whom 178 had negative and 534 had 
positive Lassa RT-PCR. Of 534 patients with confirmed 
Lassa fever, 510 (96%) participants signed informed 
consents and were included in the analysis (figure 1). Of 
Figure 1: Flow chart of participants
712 patients with suspected Lassa fever
534 had positive Lassa fever RT-PCR




178 had negative Lassa fever 
RT-PCR
24 did not give consent
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Sex 510 ∙∙ ∙∙
Male ∙∙ 258 (51%) ∙∙
Female ∙∙ 252 (49%) ∙∙
Age, years 510 ∙∙ ∙∙
<1 ∙∙ 4 (1%) ∙∙
1–4 ∙∙ 14 (3%) ∙∙
5–17 ∙∙ 66 (13%) ∙∙
18–44 ∙∙ 277 (54%) ∙∙
45–59 ∙∙ 85 (17%) ∙∙
≥60 ∙∙ 64 (13%) ∙∙
Number of people in 
household
498 6 (4–8) ∙∙
Rodents at home or in 
surrounding area
507 493 (97%) ∙∙
Contact with ill or dead 
person within 3 weeks of 
admission
506 63 (12%) ∙∙
Health workers 507 21 (4%) ∙∙
Vital signs
Level of consciousness 508 ∙∙ ∙∙
Alert ∙∙ 476 (94%) 437 (86%)
Confusion ∙∙ 20 (4%) 13 (3%)
Voice (reactive to) ∙∙ 2 (<1%) 5 (1%)
Pain (reactive to) ∙∙ 6 (1%) 9 (2%)
Unresponsive ∙∙ 4 (1%) 46 (9%)
Heart rate >110 per min 510 73 (14%) 167 (33%)
Systolic arterial pressure 
<90 mm Hg
492 26 (5%) 107 (22%)
Oxygen saturation <92% 504 34 (7%) 77 (15%)
NEWS2 484 ∙∙ ∙∙
0–2 ∙∙ 199 (41%) 34 (7%)
3–4 ∙∙ 130 (27%) 154 (32%)
5–6 ∙∙ 90 (19%) 145 (30%)
≥7 ∙∙ 65 (13%) 120 (25%)
Other clinical signs and symptoms
Fever (temperature 
>38∙0 °C)
509 389 (76%) 406 (80%)
Headache 508 187 (37%) 220 (43%)
Abdominal pain 509 157 (31%) 191 (38%)
Myalgia 510 101 (20%) 121 (24%)
Chest or retrosternal 
pain
501 59 (12%) 94 (19%)
Sore throat 508 62 (12%) 69 (14%)
Dizziness 508 127 (25%) 145 (29%)
Signs of encephalopathy
Seizure 508 12 (2%) 27 (5%)
Delirium 510 9 (2%) 18 (4%)
Meningeal syndrome 510 4 (1%) 17 (3%)
Focal deficiency 510 3 (1%) 6 (1%)









(Continued from previous column)
Aphasia or dysarthria 510 1 (<1%) 2 (<1%)
Impaired hearing or 
tinnitus
509 2 (<1%) 5 (1%)
Impaired vision 509 2 (<1%) 2 (<1%)
Vomiting 497 190 (38%) 241 (48%)
Watery diarrhoea 508 120 (24%) 148 (29%)
Hiccup 509 1 (<1%) 8 (2%)
Lower limbs oedema 510 10 (2%) 38 (7%)
Facial swelling 509 10 (2%) 17 (3%)
Cough 509 96 (19%) 118 (23%)
Bleeding, any type 510 98 (19%) 174 (34%)
Macroscopic 
haematuria
510 27 (5%) 130 (25%)
Melena 508 21 (4%) 46 (9%)
Vaginal bleeding* 228 7 (3%) 12 (5%)
Haematemesis 508 15 (3%) 15 (3%)
Gingival bleeding 510 5 (1%) 9 (2%)
Venous puncture 
point bleeding
509 2 (<1%) 7 (1%)
Haematochezia 508 6 (1%) 6 (1%)
Conjunctival bleeding 510 4 (1%) 4 (1%)
Epistaxis 509 5 (1%) 7 (1%)
Purpura 510 2 (<1%) 10 (2%)
Haemoptysis 510 2 (<1%) 2 (<1%)
Biological measures 





≥35∙0 ∙∙ 126 (27%) ∙∙
30∙0–34∙9 ∙∙ 164 (35%) ∙∙
25∙0–29∙9 ∙∙ 108 (23%) ∙∙
<25∙0 ∙∙ 68 (15%) ∙∙
Haematocrit, % 486 33 (29–38) 28 (24–33)
<25% ∙∙ 50 (10%) 153 (31%)
Platelets, 10⁹ per L 425 200 (118–300) 178 (104–269)
<80 ∙∙ 47 (11%) 60 (14%)‡






>12 ∙∙ 86 (19%) 105 (24%)
<4 ∙∙ 116 (26%) 144 (33%)
Positive malaria 
diagnostic test§
315 179 (57%) 185 (59%)
Creatininaemia, µmol/L 495 86 (65–115) 92 (73–128)




No dysfunction ∙∙ 431 (87%) 410 (83%)
KDIGO stage 1 ∙∙ 11 (2%) 18 (4%)
KDIGO stage 2 (AKI) ∙∙ 13 (3%) 10 (2%)
KDIGO stage 3 (AKF) ∙∙ 40 (8%) 57 (12%)
(Table 1 continues in next column)
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the remaining 24 patients, 15 had impaired consciousness 
at baseline and died with no relative available of whom 
consent could be asked and nine declined to take part.
Of the 510 participants, 258 (51%) were male and 
252 (49%) female. The median age was 32 years 
(IQR 21–47), with 84 (16%) participants younger than 
18 years and 426 (84%) adults (table 1). 269 (53%) 
participants came directly from their homes and 
241 (47%) were referred from other facilities (82 [16%] 
from private clinics, 34 [7%] from primary public 
facilities, and 125 [25%] from secondary or tertiary 
public facilities). The median time between 
first symptoms and admission to the Lassa fever ward 









(Continued from previous column)
Sodium, mmol/L 487 135 (131–138) 133 (129–136)
>145 ∙∙ 23 (5%) 35 (7%)
<128 ∙∙ 38 (8%) 84 (17%)
Potassium, mmol/L 482 3∙9 (3∙6–4∙4) 4∙2 (3∙8–4∙7)
>5∙0 ∙∙ 41 (9%) 73 (15%)
<3∙5 ∙∙ 99 (21%) 205 (43%)
Total carbon dioxide, 
mmol/L
479 23 (20–25) 22 (18–24)
<18 ∙∙ 75 (16%) 107 (22%)
Albumin, g/L 405 30 (26–33) 29 (24–32)
<28 ∙∙ 142 (35%) 171 (42%)
Glycaemia, mmol/L 409 4∙8 (4∙0–6∙1) 4∙2 (3∙4–5∙1)
<3∙0 ∙∙ 30 (7%) 63 (15%)
AST, U/L¶ 408 80 (48–214) 93 (52–232)
>3 times the upper 
limit of normal range
∙∙ 154 (38%) 166 (41%)
ALT, U/L¶ 421 53 (30–107) 62 (35–119)
>3 times the upper 
limit of normal range
∙∙ 80 (19%) 90 (21%)
Data are n, n (%), or median (IQR). Baseline values were collected on admission to 
hospital. For entire follow-up, values for vital signs and severity criteria are the 
poorest condition recorded at any time from baseline to end of follow-up; values 
for signs and symptoms are those reported at least once from baseline to end of 
follow-up; and values for biological measures are the poorest value recorded from 
baseline to end of follow-up. The poorest value for biological parameters was 
defined as the highest value for leucocytaemia, creatininaemia, uraemia, 
kalaemia, plasma AST and ALT; and the lowest value for haematocrit, platelet 
count, natraemia, plasma total carbon dioxide, albuminaemia, and glycaemia. 
AKF=acute kidney failure. AKI=acute kidney injury. ALT=alanine aminotransferase. 
AST=aspartate aminotransferase. Ct=cycle threshold. KDIGO=Kidney Disease–
Improving Global Outcome. NEWS2=National Early Warning Score, second 
version. *Among females aged 12 years or older. †The 466 (91%) available 
Ct values were all Ct values for the GPC gene; 44 (9%) patients had no available 
GPC gene Ct value, including  seven patients with Ct values available for the L gene 
but not for GPC and 37 patients with a positive RT-PCR test result but no available 
Ct value; these patients with no Ct value were included during the first months of 
the cohort, when Lassa fever molecular diagnostic was not done on site yet and 
samples were sent to the Irrua Specialist Teaching Hospital laboratory (Irrua, 
Nigeria), and RT-PCR results were rendered as negative or positive with no Ct 
values. ‡Of the 60 patients, two had a platelet count lower than 20 10⁹ per L, 
20 had 20–50 10⁹ per L, and 38 had 50–80 10⁹ per L. §315 participants had a 
malaria diagnostic test done between 7 days before and 4 days after admission; 
among these, 179 had at least one positive test (thick blood smear or rapid 
diagnostic test), of whom 40 had a positive thick blood smear test and a negative 
rapid diagnostic test, 119 had a positive thick blood smear test and no available 
rapid diagnostic test, 17 had a positive rapid diagnostic test and no available thick 
blood smear, and three had both tests positive; six additional participants had 
malaria diagnosed later during their hospital stay (all with a positive rapid 
diagnostic test, with thick blood smear not done). ¶The 102 (20%) AST and 
89 (17%) ALT missing values were from patients included during the second half 
of January, 2020, because the biology device used for liver function tests was out 
of order. 
Table 1: Baseline and follow-up characteristics
Participants
Length of hospital stay, days
Time to death, days (n=61) 3 (1–6)
People who were discharged alive from hospital (n=449)* 11 (10–15)
Admission in the intensive care unit† of the Lassa fever ward 94 (18%)
Ribavirin therapy
Received 510 (100%)
Time between first symptoms and first dose, days 8 (7–13)
Duration of treatment, days 10 (9–13)
Oxygen‡
Received 92 (18%)
Maximum output, L/min 6 (5–6)
Duration, days 3 (2–7)
Total blood transfusion§
Received 158 (31%)
Number of units (total blood pints) 2 (2–4)
Renal replacement therapy (intermittent haemodialysis)
Received 42 (8%)
Indications¶
Fluid overload, no response to diuretics 5 (14%)
Symptomatic hyperazotaemia 33 (94%)
Severe acid-base disorder not responding to medical 
treatment
1 (3%)






Duration, days 8 (7–10)
Antimalarial therapy||
Received 188 (37%)
Data are n (%) for category variables and median (IQR) for continuous variables. 
*One patient died after discharge. †Intensive care unit refers to a specific area of 
the Lassa fever ward where patients were more frequently monitored for vital 
functions; mechanical ventilation, vasopressive drugs, and invasive 
haemodynamic monitoring were not available. ‡Missing data for one patient. 
§Missing data for two patients. ¶Missing data for six patients; four participants 
had more than one indication for renal replacement therapy: symptomatic 
hyperazotaemia plus fluid overload not responding to diuretics (n=3) and 
symptomatic hyperazotaemia plus severe acid-base disorder not responding to 
medical treatment (n=1). ||Antimalarial therapy administered within the Lassa 
fever ward (treatments before admission are not included). 
Table 2: Care and treatments 
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patients had received antimalarials and 14 (3%) ribavirin 
therapy.
Clinical and biological features of patients on 
admission and during follow-up are presented in table 1 
and the appendix (pp 6–9). The median Ct value for 
GPC in Lassa virus RT-PCR tests at baseline was 32 
(IQR 27∙6–35∙2; appendix p 18). The most common 
clinical characteristics were fever, pain (headache, 
myalgia, chest, or abdominal pain), digestive disorders 
(vomiting or diarrhoea), neuro logical disorders (dizzi-
ness or impaired consciousness) and haemorrhagic 
signs, of which macroscopic haematuria and melena 
were the most frequent.
Overall, between baseline and end of follow-up, 
120 (25%) of 484 patients reached a NEWS2 of 7 or 
higher; 67 (14%) of 495 reached a KDIGO stage of 2 or 
higher; 174 (34%) of 510 had at least one haemorrhagic 
sign, 73 (14%) of 508 had a consciousness disorder of 
any grade; 77 (15%) of 504 had oxygen saturation lower 
than 92%; 153 (31%) of 486 had a haematocrit level lower 
than 25%; 90 (21%) of 421 had plasma alanine 
aminotransferase over three times the upper limit of 
normal; and 171 (42%) of 405 had albuminaemia lower 
than 28 g/L. Male patients had more frequent acute 
kidney injury and acute kidney failure and elevated 
alanine aminotransferase at baseline than did female 
patients (appendix p 10).
All participants received intravenous ribavirin therapy 
for a median of 10 days (IQR 9–13; table 2). Ribavirin was 
started a median of 8 days (7–13) from the onset of 
symptoms. 92 (18%) participants received oxygen 
therapy, 158 (31%) had at least one blood transfusion, and 
42 (8%) underwent dialysis. Of the 510 participants, 
130 still had a positive Lassa virus RT-PCR at day 10, 53 at 
day 15, 30 at day 20, and 12 at day 25 (appendix p 19). The 
median time to hospital discharge in patients who 
survived was 11 days (IQR 10–15).
62 (12%) participants died, including five (6%) of 
84 children (four girls and one boy, aged 2 weeks, 4 months, 
1 year, 12 years, and 15 years) and 57 (13%) of 426 adults. 
The median time to death was 3 days (IQR 1–6). Death 
occurred within 18 days of the onset of symptoms for 
48 (81%) of 59 participants with a known date of 
first symptoms (appendix p 20). Of the 62 deaths, 
51 occurred within 7 days of hospital admission, seven 
between 8 and 19 days, and four more than 20 days after 
admission (appendix p 21). The four patients who died 
after 20 days were a 33-year-old man and two women 
(22 and 45 years) who developed acute kidney failure 
and underwent dialysis, and a 76-year-old woman 
with persisting hyponatraemia and severe hepatitis after 
completing her treatment for Lassa fever (her post-
treatment RT-PCR was negative). All but one death 
occurred in hospital. The participant who died after 
hospital discharge was a 2-week-old girl at the time of 
admission. She was discharged at day 12 and died at 
home 1 week later. Her cause of death was unknown. 
In univariable analysis, the risk of death increased 
significantly with increasing age and with the following 
baseline characteristics: high body-mass index, impaired 
consciousness, at least one other sign of encephalopathy, 
low oxygen saturation, accelerated heart rate, watery 
diarrhoea, at least one sign of bleeding, low platelet count, 
high leucocyte count, high neutrophil count, high uraemia, 
high creatininaemia, hypernatraemia, hyperkalaemia, low 
total carbon dioxide, low albuminaemia, high plasma 
aspartate aminotransferase or alanine aminotransferase, 
high plasma bilirubin, high KDIGO grade, high NEWS2 
score, low Lassa fever RT-PCR Ct value, and dipstick 
haematuria (appendix pp 11–15).
We observed no association between mortality and sex, 
time from first symptoms to hospital admission, time 
from first symptoms to ribavirin treatment start, a 
positive malaria test, pregnancy, or any other symptoms 
or test results (appendix pp 11–15).
In multivariable analysis, age, NEWS2, KDIGO stage, 
plasma alanine aminotransferase, and RT-PCR Ct value 
were independently associated with the risk of death (final 
model, table 3; findings from a sensitivity analysis 
including patients with missing values are presented in 
the appendix [p 16]). The probability of death at day 30 
was 7∙2% for participants younger than 45 years and 
24∙8% for those aged 45 years or older; 3∙5% for 
participants with baseline NEWS2 of 0–2, 7∙7% for those 
Available 






Crude odds ratio 
(95% CI)




Female 252 28 (11%) 1 (ref) ∙∙ 1 (ref) ∙∙
Male 258 34 (13%) 1∙21 (0∙71–2∙07) 0∙48 1∙19(0∙45–3∙16) 0∙72
Age, years
<45 361 25 (7%) 1 (ref) ∙∙ 1 (ref) ∙∙
≥45 149 37 (25%) 4∙44 (2∙56–7∙70) <0∙0001 16∙30 (5∙31–50∙30) <0∙0001
NEWS2
<7 419 30 (7%) 1 (ref) ∙∙ 1 (ref) ∙∙
≥7 65 30 (46%) 11∙10 (6∙02–20∙50) <0∙0001 4∙79 (1∙75–13∙10) 0∙0023
Plasma ALT
<3 ULN 341 21 (6%) 1 (ref) ∙∙ 1 (ref) ∙∙
≥3 ULN 80 23 (29%) 6∙15 (3∙19–11∙80) <0∙0001 4∙96 (1∙69–14∙60) 0∙0036
KDIGO stage
<2 442 26 (6%) 1 (ref) ∙∙ 1 (ref) ∙∙
≥2 53 28 (53%) 17∙90 (9∙18–35∙00) <0∙0001 7∙52 (2∙66–21∙20) <0∙0001
Lassa RT-PCR Ct
≥30 290 8 (3%) 1 (ref) ∙∙ 1 (ref) ∙∙
<30 176 46 (26%) 12∙50 (5∙72–27∙20) <0∙0001 4∙65 (1∙50–14∙50) 0∙0078
Data are n (%) unless otherwise specified. ALT=alanine aminotransferase. Ct=cycle threshold (GPC gene as a target). 
KDIGO=Kidney Disease-Improving Global Outcome. NEWS2=National Early Warning Score, second version. ULN=upper 
limit of normal range. 
Table 3: Association between mortality and baseline characteristics, multivariable analysis (n=377)
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Figure 2: Kaplan-Meier 
probability of death, 







Early Warning Score, second 
version. ULN=upper limit of 
normal range. 
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with NEWS2 3–4, 14∙4% for those with NEWS2 5–6, and 
46∙2% for those with NEWS2 of 7 or higher; 5∙9% for 
participants with a baseline KDIGO stage of 0–1 and 
52∙8% for those with KDIGO stage of 2–3; 6∙2% for 
participants with baseline plasma alanine aminotrans-
ferase values lower than 3∙0 times the upper limit of 
normal, 18∙2% for those with values 3∙0–4∙9 times the 
upper limit of normal, and 36∙2% for those with values of 
5∙0 or more times the upper limit of normal; and 
42∙6% for participants with a baseline Ct value lower than 
25∙0, 15∙7% for those with Ct 25∙0–29∙9, 4∙3% for those 
with Ct 30∙0–34∙9, and 0∙8% for those with Ct 35∙0 or 
higher (figure 2). The distribution of baseline Ct values for 
Lassa fever RT-PCR by age and baseline NEWS2, KDIGO 
grade, and plasma alanine aminotransferase value is 
detailed in the appendix (p 17).
Of the 172 women of childbearing age, seven (4%) 
reported a recent miscarriage between the onset of 
symptoms and hospital admission and 17 (10%) were 
pregnant on admission. Of these 17 ongoing pregnancies, 
12 ended while the participant was in hospital and 
two ended after hospital discharge (5 days and 5 weeks 
after discharge). The three remaining women were 
discharged while still pregnant and their pregnancy 
outcome was still unknown at the time of the analysis. 
The 14 documented pregnancy outcomes were 
six spontaneous miscarriages, one intrauterine death, 
one maternofetal demise, and six livebirths. The 
maternofetal demise occurred on day 0. All six live 
newborn babies tested negative for Lassa fever.
Discussion 
To our knowledge, this is the first prospective study of 
patients with acute symptomatic Lassa fever confirmed 
by RT-PCR. Patients received appropriate care in a 
specific Lassa fever ward, including the possibility of 
oxygen therapy, blood transfusion, and dialysis. All 
received intravenous ribavirin in accordance with 
national and international guidelines. Our findings 
provide a comprehensive description of clinical and 
biological characteristics of Lassa fever and their 
relationship with mortality. More importantly, they 
provide prospective estimates from a large population 
for key parameters that will be useful for designing 
future therapeutic trials.
In this study, the frequency of haemorrhagic signs was 
higher than that reported at a national level in Nigeria.13 
The disease displayed a lower mucosal haemor rhaging 
pattern, in which macroscopic haematuria, melena, and 
vaginal bleeding were the most frequent mani festations. 
Thrombopenia was common and moderate.20,21 These 
findings suggest that haemorrhaging might be driven 
by platelet dysfunction,20,22 endothelial dysfunction,22 
and coagulopathy21 rather than thrombocytopenia. We 
observed a high frequency of hypoalbuminaemia, which 
might be due to inflammation, digestive loss, renal 
loss, or vascular leakage.23 Kidney dysfunction and its 
complications (acidosis, hyperkalaemia, and hyperazo-
taemia) was a dominant feature and a major risk factor 
for death. However, mortality in patients with severe 
kidney dysfunction was lower than previously reported,8 
possibly because of the early access to free-of-charge 
dialysis. High plasma aminotransferase levels were 
frequent.6,8,24 This was truer for aspartate aminotrans-
ferase than for alanine aminotransferase, suggesting 
that, beyond hepatic tissular damage,21,25 some degree of 
haemolysis or myolysis might occur. Finally, our data 
show that Lassa fever greatly influences pregnancy 
outcomes. Seven (4%) women of childbearing age 
reported miscarriages between the onset of symptoms 
and hospitalisation. 17 (10%) women were pregnant on 
hospital admission and eight (57%) of 14 ongoing 
pregnancies ended with the death of the baby during the 
hospital stay.19,26
All participants received ribavirin therapy. The time 
between first symptoms and administration of ribavirin 
was not associated with mortality, contrary to a previous 
report.6 The proportion of patients with a haematocrit 
level below 25% increased from 10% at baseline to 
31% over the entire study follow-up. Ribavirin-induced 
haemolysis might have occurred even where multiple 
potential causes of anaemia existed in this context, 
such as inflammation, massive fluid administration, 
or haemorrhaging. Most deaths occurred within the 
first few days. This, together with the 9-day delay between 
first symptoms and hospital admission, suggests that 
special efforts should be made to promote earlier 
diagnosis and faster hospitalisation.
When designing future comparative trials, the expected 
mortality rate in the reference group will be key for 
calculating the number of participants needed. In this 
study, 62 (12%) patients with Lassa fever died, including 
57 (13%) of 426 adults and five (6%) of 84 children. These 
numbers are conservative estimates because some 
patients who died shortly after admission to hospital 
could not be asked for informed consent and thus were 
not included in the analysis. However, we suggest that 
trials comparing new Lassa fever treatments to a standard 
of care should take no more than 15% as the reference 
mortality rate. Given such a mortality rate in the reference 
group of any trial, large numbers of participants would 
be required to show that a new treatment can decrease 
mortality. Therefore, future trial investigators might con-
sider using a composite endpoint, combining mortality 
with a clinically signifi cant indicator of adverse outcome. 
We suggest that the worsening of the KDIGO stage and 
the need for dialysis could be a valuable candidate, 
because acute kidney failure is a cause of death but 
renal-associated death can be avoided if the standard of 
care includes dialysis. Because of the strong association 
between mortality and baseline Ct value, alanine amino-
transferase value, NEWS2, and KDIGO stage, future 
trial investigators might also consider stratifying the 
randomisation by one or more of these variables.
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Although no prespecified universal cutoff exists for 
Ct values for Lassa fever RT-PCR assays, we believe that 
all participants in our study were confirmed cases of 
Lassa fever. The bell-shaped distribution of the observed 
Ct values is consistent with a cutoff value at 42 in our 
setting (appendix p 18). Patients with high Ct values had 
much lower mortality rates than those with low Ct values, 
in the same order of magnitude as previously reported in 
patients with Ebola. This suggests that Ct values are a 
suitable surrogate for viral load and a useful tool in Lassa 
fever as well as in Ebola, two diseases where viral load is 
strongly associated with mortality.27
Our study had several limitations. First, the study 
was not designed to provide new evidence on the 
benefit–risk ratio of ribavirin, which is still needed. 
Second, leucocytosis and high neutrophil counts were 
more frequent in patients who died. However, bacterial 
cultures were not routinely available. Even if leucocytosis 
could be due to a stress response in patients with 
multiorgan failure, it would have been interesting to 
document the frequency of bacterial morbidity and its 
potential prognostic value. Third, several other biological 
variables—such as clotting parameters, inflammatory 
markers, platelet function, and stigmas of haemolysis 
or myolysis—were not available, which limits our ability 
to discuss the pathogenesis underlying some disease 
features. Finally, we used multivariable logistical regres-
sion to analyse the association between mortality and 
several key characteristics previously shown to be 
associated with mortality in Ebola virus disease. Our 
findings are consistent with the hypothesis that there are 
common clinical and biological features between Ebola 
and Lassa fever, even if mortality is much higher with 
Ebola virus disease than with Lassa fever. However, we 
should point out that odds ratios are not relative risks, 
and thus the magnitude of the odds ratios we present 
here does not reflect the respective clinical importance of 
one variable relative to the others.28 Additionally, we did 
not find any significant association between mortality 
and other characteristics such as sex or the time from 
first symptoms to ribavirin treatment start, but the 
absence of association in a sample of patients does not 
prove the absence of association in the population.29
In conclusion, this study provides prospective evidence 
on Lassa fever characteristics under the best possible 
standard of care in Nigeria. Future studies should explore 
whether survival could be improved by upgrading the 
standard of care and whether ribavirin should continue 
to be part of this standard. Whether the standard of care 
includes ribavirin or not, future comparative therapeutic 
trials should actively promote early diagnosis and 
consider using a composite outcome and stratifying 
randomisation by baseline Ct value and a clinical or 
biological severity score.
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